Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Maria Agnese Fabbri

Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)

Scientific Reports

Multidisciplinary

English

Related publications

P1.01-93 Quality of Life in Patients With Advanced NSCLC Treated in Second- Or Third-Line With Nab-Paclitaxel + Durvalumab: ABOUND.2L+

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review

Journal of Thoracic Oncology

Respiratory Medicine

English

KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer

Cancer Research

Respiratory Medicine

English

P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine

Internal Medicine

English

P1.01-70 Efficacy and Safety of Second- Or Third-Line Nab-Paclitaxel + Durvalumab in Patients With Advanced NSCLC (ABOUND.2L+)

Journal of Thoracic Oncology

Respiratory Medicine

English

Docetaxel as Second Line After Failure of Gemcitabine/Cisplatin Regimen in Advanced and/or Metastatic Urinary Bladder Cancer Patients in Egypt

Research in Oncology

English